Message #35 From:
Stock News Bot Date: January 16, 2007 05:00:00 AM
OXIS News OXIS International Appoints Matt Spolar to Its Board of Directors
FOSTER CITY, Calif.--(BUSINESS WIRE)--OXIS International (OTCBB: OXIS) (Nouveau Marche: OXIS) (FWB:
OXI), a biopharmaceutical company focused on commercializing biomarker
research and clinical assays, nutraceutical and therapeutic products
related to oxidative stress and, through its majority interest in
BioCheck, high quality immunoassay clinical kits and contract services,
announced today that it has appointed Matt Spolar to its Board of
Directors. Mr. Spolar currently serves as Vice President, Product
Technology for Atkins Nutritionals, Inc.(“Atkins”),
a market-leading portable nutrition foods company.
Since 1999, Mr. Spolar has spearheaded new product development, product
optimization, scientific affairs, quality systems management, and
technical production support for Atkins. Mr. Spolar helped to arrange an
acquisition of Atkins by Parthenon Capital and Goldman Sachs in October,
2003 for more than $500 million, participated in improving the company’s
balance sheet through a pre-packaged bankruptcy where two-thirds of
liabilities were exchanged for equity, and witnessed the company’s
emergence from bankruptcy just six months later.
”We are pleased to attract an experienced
executive like Matt to our Board of Directors during such an exciting
time for OXIS,” said Marvin S. Hausman MD,
President and CEO. “We believe his experience
in turnaround situations and in developing innovative food products
should be invaluable as we aggressively drive sales, seek licensing
activities, and launch one of our leading nutraceutical products from
our promising portfolio.”
Prior to joining Atkins, Mr. Spolar served as an analyst with
Datamonitor, Inc., a global management consultancy, where he specialized
in providing information solutions for Fortune 500 consumer packaged
goods companies. Mr. Spolar was awarded BS and MS degrees in Food
Science from the Pennsylvania State University.
About OXIS and BioCheck:
OXIS International, Inc. develops technologies and products to research,
diagnose, treat and prevent diseases of oxidative stress/inflammation
associated with damage from free radical and reactive oxygen species.
The company holds the rights to three therapeutic classes of compounds
in the area of oxidative stress, and has focused commercialization
programs in clinical cardiovascular markers, including MPO
(myeloperoxidase) and GPx (glutathionione peroxidase), as well as a
highly potent antioxidant, Ergothioneine, that may be sold
over-the-counter (OTC) as a neutraceutcal supplement. OXIS has acquired
a 51% interest in and has the option to purchase the remaining 49% of
BioCheck.
BioCheck, Inc. is a leading provider of high quality enzyme immunoassay
research services and products including immunoassay kits for cardiac
and tumor markers, infectious diseases, thyroid function, steroids, and
fertility hormones. The company operates a 15,000 square-foot, U.S. Food
and Drug Administration (FDA) certified cGMP, and ISO
device-manufacturing facility in Foster City, California.
The statements in this press release that are not purely historical are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934, including, without limitation, statements regarding our
expectations, objectives, anticipations, plans, hopes, beliefs,
intentions or strategies regarding the future. Factors that could cause
actual results to differ materially from the forward-looking statements
include risks and uncertainties indicated in the company's filings with
the Securities and Exchange Commission. It is important to note that
actual outcomes could differ materially from those in such
forward-looking statements.
